NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance

NEOGENOMICS INC

Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).
Net loss widened 142% to $45M including $20M impairment charges.
Adjusted EBITDA flat at $10.7M vs $10.9M last year.
Full-year 2025 revenue guidance cut to $720-$726M (prev $747-$759M); Adj EBITDA guidance lowered to $41-$44M.
Acquired Pathline for $8M cash plus $1M contingent consideration in April 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.